Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study
A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new
information regarding cancer rates and types in these disorders.
Mutations in IBMFS genes are relevant to carcinogenesis in sporadic cancers.
Patients with IBMFS who develop cancer differ in their genetic and/or environmental features
from patients with IBMFS who do not develop cancer.
These cancer-prone families are well suited for cancer screening and prevention trials
targeting those at increased genetic risk of cancer.
Carriers of IBMFS gene mutations are at increased risk of cancer.
The prototype disorder is Fanconi's Anemia (FA); other IBMFS will also be studied.
To determine the types and incidence of specific cancers in patients with an IBMFS.
To investigate the relevance of IBMFS gene mutations in the carcinogenesis pathway of the
sporadic counterparts of IBMFS-associated cancers.
To identify risk factors for IBMFS-related cancers in addition to the primary germline
To determine the risk of cancer in IBMFS carriers.
North American families with a proband with an IBMFS.
IBMFS suspected by phenotype, confirmed by mutation in an IBMFS gene, or by clinical
Fanconi's anemia: birth defects, marrow failure, early onset malignancy; positive chromosome
Diamond-Blackfan anemia: pure red cell aplasia; elevated red cell adenosine deaminase.
Dyskeratosis congenita: dysplastic nails, lacey pigmentation, leukoplakia; marrow failure.
Shwachman-Diamond Syndrome: malabsorption; neutropenia.
Amegakaryocytic thrombocytopenia: early onset thrombocytopenia.
Thrombocytopenia absent radii: absent radii; early onset thrombocytopenia.
Severe Congenital Neutropenia: neutropenia, pyogenic infections, bone marrow maturation
Pearson's Syndrome: malabsorption, neutropenia, marrow failure, metabolic acidosis; ringed
Other bone marrow failure syndromes: e.g. Revesz Syndrome, WT, IVIC, radio-ulnar synostosis,
First degree relatives of IBMFS-affected subjects as defined here, i.e. siblings (half or
full), biologic parents, and children.
Grandparents of IBMFS-affected subjects.
Patients in the general population with sporadic tumors of the types seen in the IBMFS (head
and neck, gastrointestinal, and anogenital cancer), with none of the usual risk factors
(e.g. smoking, drinking, HPV).
Natural history study, with questionnaires, clinical evaluations, clinical and research
laboratory test, review of medical records, cancer surveillance.
Primary endpoints are all cancers, solid tumors, and cancers specific to each type of IBMFS.
Secondary endpoints are markers of pre-malignant conditions, such as leukoplakia, serum or
tissue evidence of carcinogenic viruses, and bone marrow morphologic myelodyplastic syndrome
or cytogenetic clones.
Blanche P Alter, M.D.
National Cancer Institute (NCI)
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Bethesda, Maryland 20892|